Risk Management: FDA and Industry Experience. Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.
|
|
- Charity Stafford
- 6 years ago
- Views:
Transcription
1 Risk Management: FDA and Industry Experience Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.
2 Disclaimer This presentation contains a summary of the opinion and perspective from GPhA member industry representatives on the topic of Risk Management: FDA and Industry Experience. This presentation does not necessarily represent the opinion of the presenter nor Mylan Pharmaceuticals Inc..
3 Risk Management and ANDA Review Under GDUFA review goals are mandated. Risk Ranking is being used by the agency to rate applications prior to review. The goal for risk ranking would be to save time on simple applications and apply the time to more complex applications. In aggregate this should speed up the review process.
4 Why Are We Talking About Risk GDUFA Goals Management Today 1. Enhanced SAFETY through risk based inspection parity for all participants 2. Improve ACCESS to generics through more timely and predicable approvals 3. Better TRANSPARENCY through improved feedback and communication with industry
5 Why Are We Talking About Risk GDUFA Goals Management Today 1. Enhanced SAFETY through risk based inspection parity for all participants 2. Improve ACCESS to generics through more timely and predicable approvals 3. Better TRANSPARENCY through improved feedback and communication with industry
6 Why Are We Talking About Risk GDUFA Goals Management Today 1. Enhanced SAFETY through risk based inspection parity for all participants 2. Improve ACCESS to generics through more timely and predicable approvals 3. Better TRANSPARENCY through improved feedback and communication with industry
7 Current OGD Workload According to Activities Report of the Generic Drug Program A change in the review philosophy seems necessary. FDA has indicated that Risk Management of ANDAs is a mechanism for that change.
8 ICH Q9 Guidance for Industry Quality Risk Management ICH Q9 was finalized in June of From ICH Q9 Principles of Quality Risk Management. The evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient; and The level of effort, formality, and documentation of the quality risk management process should be commensurate with the level of risk.
9 What is risk? Manufacturing Risk Based on prior knowledge, what is the quality risk of the chosen manufacturing process? Do the critical quality attributes of the drug product address these risks? Drug risk What is the inherent risk based upon the drug product and its potential affect on the patient? Do the critical quality attributes of the drug product address these risks?
10 Manufacturing Risk The more complicated the process, the greater the risk? Looks like we have already weighed in on this question. QbD IR example product development report is 107 pages. QbD MR example product development report is 161 pages. How do we account for the experience of the firm on similar processes to mitigate those risks. Can Quality Metrics for the firm/site be used to decrease the risk ranking? Does familiarity with the process decrease the risk ranking?
11 Drug Risk? Risk from the drug product itself must be considered. What categories will require additional level of effort, formality, and documentation of the quality risk? FDA and Industry should work together and transparently to achieve a common understanding of which drugs and or drug categories will require this effort.
12 Tools for Risk Assessment ICH Q9 suggests several methodologies. All methodologies share three basic elements. Risk Identification What might go wrong? Risk Analysis What is the likelihood of the occurance? Risk Evaluation How does the risk compare to the risk criteria?
13 Tools for Risk Assessment ICH Q9 suggests several methodologies. Basic risk management facilitation methods (flowcharts, check sheets etc.); Failure Mode Effects Analysis (FMEA); Failure Mode, Effects and Criticality Analysis (FMECA); Fault Tree Analysis (FTA); Hazard Analysis and Critical Control Points (HACCP); Hazard Operability Analysis (HAZOP); Preliminary Hazard Analysis (PHA); Risk ranking and filtering; Supporting statistical tools.
14 FDA Risk Management and Industry Perspective Call for collaboration and transparency. Similar to efforts on QbD, the Agency should work with industry to assure that the details of the algorithm used are clear Work with Industry to provide guidance on any risk ranking that is based on the molecule and independent of the manufacturing process. Assure that resources are balanced so that complex drugs are approved in a timely and predictable fashion despite the increased Risk Ranking. Complex products with more risk should have adequate resources applied to their review. Complex products and their associated risk should not delay access to affordable generic drug products.
Systematic Risk Management: An Overview of ICH Q-9
Systematic Risk Management: An Overview of ICH Q-9 March 12, 2014 12014 ParagonRx International LLC Today s Session Systematic Risk Management: An Overview of ICH Q-9 Speakers: Jeff Fetterman, President,
More informationQUALITY RISK MANAGEMENT (QRM) TOOLKIT
QUALITY RISK MANAGEMENT (QRM) TOOLKIT Amanda Bishop McFarland Senior Continuous Process Improvement Analyst Global Quality Risk Management Genzyme, A Sanofi Company Disclaimers The material and perspectives
More informationUpdates on Quality Metrics - Industry Perspectives Dan Snider Vice President, Research and Development Mylan Inc.
GPhA/FDA FALL TECHNICAL CONFERENCE Updates on Quality Metrics - Industry Perspectives Dan Snider Vice President, Research and Development Mylan Inc. Disclaimer This presentation contains a summary of the
More informationRisk Based Validation. Why, How and with what tools?
Risk Based Validation Why, How and with what tools? Tech Talk Agenda History of FDA GMP initiative for the 21 st Century. Industry response to FDA initiative. Harmonisation through ICH. ASTM Standard on
More informationTRAINING TITLE: Quality Risk Management Certification (CERT-004)
TRAINING TITLE: Quality Risk Management Certification (CERT-004) OVERVIEW: The importance of quality systems has been recognized in the life sciences industry and it is becoming evident that quality risk
More informationProcess Design Risk Management A Proactive Approach
Page 1 of 7 Guest Column August 30, 2017 Process Design & Risk Management A Proactive Approach By Sandra Wassink, Principal Process Engineer, Pharmatech Associates The FDA has given us the green light
More informationQuality Risk Management
Quality Risk Management Audit Expectations and Observations Matthew Davis Lead Auditor Office of Manufacturing Quality, TGA CAPSIG 4 th May 2011 www.tga.gov.au 2 QRM - TGA Expectations and Observations
More informationANDAs: Stability Testing of Drug Substances and Products- Industry Perspective
GPhA/FDA FALL TECHNICAL CONFERENCE ANDAs: Stability Testing of Drug Substances and Products- Industry Perspective Nick Cappuccino, Jr., Ph.D., Vice President Scientific Affairs, Dr. Reddy s Laboratories,
More informationRobert Posgai Director of Materials Procurement, Biogen (BPOG)
Keynote Speaker Building the Foundations for Excellence in Biopharmaceutical Raw Material Supply Chain and Impact of Modality on Excipient Expectations Robert Posgai Director of Materials Procurement,
More informationThe Role of Quality Risk Management in New Drug Development and Manufacturing
The Role of Quality Risk Management in New Drug Development and Manufacturing CASSS CMC Strategy Forum Bethesda, MD July 27, 2009 Terrance Ocheltree, RPh, PhD Pharmaceutical Assessment Lead (Acting) Office
More informationGDUFA Past & Present
GDUFA Past & Present David R. Gaugh, R.Ph. Senior Vice President for Sciences and Regulatory Affairs Generic Pharmaceutical Association June 15, 2015 About GPhA GPhA represents the manufacturers and distributors
More informationROLE OF ICH GUIDELINES IN PHARMACEUTICAL QUALITY RISK MANGAMENT- REVIEW
ejpmr, 2016,3(7), 161-169. SJIF Impact Factor 3.628 Review Article EUROPEAN JOURNAL European OF PHARMACEUTICAL Journal of Pharmaceutical and Medical Research AND MEDICAL RESEARCH ISSN 2394-3211 www.ejpmr.com
More informationEvolution of the CMC Review - ANDAs
Evolution of the CMC Review - ANDAs Susan Rosencrance, Ph.D. Director (Acting), Office of Lifecycle Drug Products Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research October 6,
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More informationM. Sc. Dissertation. Implementation of a Quality Risk Management Approach to Commissioning and Qualification in the Biopharmaceutical Industry
M. Sc. Dissertation Implementation of a Quality Risk Management Approach to Commissioning and Qualification in the Biopharmaceutical Industry Eamon O Connor This project is submitted in part fulfilment
More informationISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE September/October 2008, Vol. 28 No. 5 This executive summary provides an overview of the second edition of the ISPE Baseline Guide:
More informationCONTENTS 1 INTRODUCTION The Regulatory Focus on Quality Risk Management Objectives of Risk Assessment and Risk Management: The Key Concepts Key Terms in Relation to Risk and Risk Assessment Structure of
More informationParadigm Change in Manufacturing Operations SM
Technical Report No. 54-3 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products
More informationQuestion-based Review: A New Quality Assessment System for Generic Drugs
Question-based Review: A New Quality Assessment System for Generic Drugs Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs Food and Drug Administration IFPAC Annual Meeting, Jan. 25-28,
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationOpportunities, Challenges and Benefits of using HACCP as a Quality Risk Management Tool in the Pharmaceutical Industry
Opportunities, Challenges and Benefits of using HACCP as a Quality Risk Management Tool in the Pharmaceutical Industry Saurabh Dahiya 1,, Roop K. Khar 1 and Aruna Chhikara 2 1 Department of Pharmaceutics,
More informationCDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018
CDER Keynote Address Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA AAM GRx+Biosims Conference September 5, 2018 1 Outline CDER s modernization roadmap Initiatives to facilitate
More informationPAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland
PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &
More informationParadigm Change in Manufacturing Operations SM
Technical Report No. 54-2 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 1: Case Study Examples for Quality Risk Management in Packaging and
More informationReal Time Communication Inception and Evolution
Real Time Communication Inception and Evolution 2016 GPhA CMC Workshop May 17, 2016, Bethesda, MD Glen Jon Smith, M.S., M.A.S. Deputy Director (Acting) Office of Lifecycle Drug Products, OPQ, CDER 1 What
More informationComments from Cross-Industry Quality Metrics Collaboration Group regarding Docket FDA D-2537: Request for Quality Metrics.
November 25, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane Room 1061 Rockville, MD 20852 Comments from Cross-Industry
More informationRISK ASSESSMENT IN PHARMACEUTICAL MICROBIOLOGY
RISK ASSESSMENT IN PHARMACEUTICAL MICROBIOLOGY Ivana Jovanovska-Klincarska 1*, Ilina Popovska 1, Vladimir Kostovski 1, Jelena Dimitrovska 1, Ema Kikovska-Stojanovska 1, Sonja Ugarkovic 1 1 Research and
More informationRisk Management from the Point of View of a Competent Authority
Risk Management from the Point of View of a Competent Authority Rudolf Völler GMP Inspectorate, Regierungspräsidium, Darmstadt (Germany) Summary A working risk evaluation system is a key element of drug
More informationAPI Selection of Starting Materials Impact on First Cycle Approval
API Selection of Starting Materials Impact on First Cycle Approval Presented by Aloka Srinivasan, Ph.D. Vice President, Regulatory Affairs May 24, 2017 Trends in Selection of Regulatory Starting Materials
More informationCopyright 2004 The Pharmaceutical & Healthcare Sciences Society
Whyte, W., and Eaton, T. (2004) Microbiological contamination models for use in risk assessment during pharmaceutical production.european Journal of Parenteral and Pharmaceutical Sciences, 9 (1). pp. 11-15.
More informationAutomated System Validation By: Daniel P. Olivier & Curtis M. Egan
Automated System Validation By: Daniel P. Olivier & Curtis M. Egan In today s technical environment validation practices are both a requirement and an important tool in the medical and pharmaceutical industry.
More informationQuality by Design: An Attempt to Jumpstart. Peter Calcott, Ph.D. President, Calcott Consulting
Quality by Design: An Attempt to Jumpstart Innovation Into the Manufacturing Process Peter Calcott, Ph.D. President, Calcott Consulting GMP in the 21 st Century Quality by Design (QbD) is part of Critical
More informationIntroductions and Perspectives on International Harmonization
Introductions and Perspectives on International Harmonization FDA/PQRI Conference on Evolving Product Quality September 17 th 2014 Mark Rosolowsky, PhD Vice President Global Regulatory Sciences CMC Bristol-Myers
More informationThe IPEC Risk Assessment Guide for Pharmaceutical Excipients. Part 1 Risk Assessment for Excipient Manufacturers
The IPEC Risk Assessment Guide for Pharmaceutical Excipients Part 1 Risk Assessment for Excipient Manufacturers First Version 2017 This document represents voluntary guidance for the pharmaceutical excipient
More informationTHE PACMP STRATEGY. March 13-16, 2018
THE PACMP STRATEGY FDA/Xavier PharmaLink Conference 2018 March 13-16, 2018 Ajay Pazhayattil, Director- Pharmaceutical Development, AvacaPharma Inc., Vienna, VA ajay.pazhayattil@avacapharma.com PACMP ICH
More informationThe Future of Generic Pharmaceuticals
The Future of Generic Pharmaceuticals David R. Gaugh, R.Ph. Senior Vice President, Sciences and Regulatory Affairs Generic Pharmaceutical Association A Look Ahead Aging Demographics 1 YEARS OF AGE A Look
More informationRISK MANAGEMENT. ASQ Orange Empire Section 2017 Quality Day
RISK MANAGEMENT BOB MEHTA MSQA, MBA, B.S. (CHEM), ASQ- FELLOW, CSSBB, CQE, CRE, CSQE, CBA, CQA, CPGP, CHA PRINCIPAL CONSULTANT & RECRUITER GMP ISO EXPERT SERVICES E-MAIL: CONTACT@GMPISOEXPERT.COM PHONE:
More informationHow we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.
2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. The information within this presentation
More informationHUMAN FACTORS ENGINEERING: DESIGN OF MEDICAL DEVICES
HUMAN FACTORS ENGINEERING: DESIGN OF MEDICAL DEVICES Chapter 5 Prof. Yasser Mostafa Kadah Managing the risk of use error Reports compiled by the Food and Drug Administration (FDA) indicate that as many
More informationSingapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum
Singapore Clinical Research Professional (CRP) /Clinical Research Coordinator Society (CRCS) Forum 25 August 2017 TOPIC: Issue Management / Quality Risk Management Implications with ICH GCP E6 (R2) and
More informationQuality Risk Management & food safety management
Quality Risk Management & food safety management by Tina Beck Hansen Quality Risk Management (http://www.ich.org/fileadmin/public_web_site/ich_pro ducts/guidelines/quality/q9/step4/q9_guideline.pdf) ICH
More informationWHO guidelines on quality risk management
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Regulatory Affairs Rx Perrigo Company, plc Q U A L I T Y A F F O R D
More informationGDUFA Policy Development Hearing
GDUFA Policy Development Hearing David R. Gaugh, R.Ph. Senior Vice President for Sciences and Regulatory Affairs Generic Pharmaceutical Association September 17, 2014 About GPhA GPhA represents the manufacturers
More informationCurrent Topics For Sterile Generic Drug Products
Current Topics For Sterile Generic Drug Products Marla Stevens-Riley, Ph.D. Team Leader Division of Microbiology for ANDA Review FDA/CDER GPHA CMC Workshop June 4, 2014 Disclaimer Opinions expressed in
More informationPrioritizing and Managing Key CMC Elements
Prioritizing and Managing Key CMC Elements Using 21 st Century Principles during Early Development Laurie Graham Product Quality/CMC Reviewer FDA/CDER/OPS/OBP Division of Monoclonal Antibodies 1 Disclaimer
More informationCOMPARISON OF PROCESS HAZARD ANALYSIS (PHA) METHODS
COMPARISON OF PROCESS HAZARD ANALYSIS (PHA) METHODS by Primatech Inc. The hazard and operability (HAZOP) study is the most commonly used process hazard analysis (PHA) method. However, there are many other
More informationCLEANING VALIDATION WITH RISK ASSESSMENT
CLEANING VALIDATION WITH RISK ASSESSMENT Bangkok, Thailand July 26 2017 Jairaj (Jai) Mehta, Consultant, Promoting the Quality of Medicines 2016. ALL RIGHTS RESERVED. Presentation Outline: Cleaning Validation
More informationICH Q12 Perspectives: The Robust PQS
ICH Q12 Perspectives: The Robust PQS PQRI October 5 th, 2015 Mahesh Ramanadham, Pharm.D./MBA Branch Chief, Inspection Assessment Branch 2 Division of Inspection Assessment Office of Process and Facilities
More informationUSING OPERATIONAL EXCELLENCE (OPEX) AND LEAN MANAGEMENT TO IMPROVE ORGANIZATIONAL INTELLIGENCE
PHARMATALK 11 TH MAY 2015 BERLIN USING OPERATIONAL EXCELLENCE (OPEX) AND LEAN MANAGEMENT TO IMPROVE ORGANIZATIONAL INTELLIGENCE Dr. Joerg Tautrim Strategic Lean consultant, Director Lean Institute Germany
More informationQuality Risk Management and Submission Strategies for Breakthrough Therapies
Quality Risk Management and Submission Strategies for Breakthrough Therapies IFPAC/Washington DC January 22, 2014 Sarah Pope Miksinski, Ph.D. Acting Director, Division of New Drug Quality Assessment 2
More informationProcess Analytical Technologies View Point of the Regulators
Process Analytical Technologies View Point of the Regulators Jean-Louis ROBERT, Ph.D. Chair QWP Laboratoire National de Santé Luxembourg Cannes, 3 May 2004 1 Process analytical Technologies This presentation
More informationA Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy
A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,
More informationReal-Time Communication During the CMC Review with the Office Of Pharmaceutical Quality (OPQ)
Real-Time Communication During the CMC Review with the Office Of Pharmaceutical Quality (OPQ) Real-Time Communication Webinar December 5, 2014 Susan Rosencrance Acting Director, Office of Lifecycle Drug
More informationFMEA Failure Mode Effects Analysis. ASQ/APICS Joint Meeting May 10, 2017
FMEA Failure Mode Effects Analysis ASQ/APICS Joint Meeting May 10, 2017 FMEA (Failure Mode and Effects Analysis) Failure Mode and Effects Analysis Agenda What is it? Motivation FMEA Methods Examples What
More informationIdentification and Control of Critical Process Points Using Complementary Risk Assessments (corrected)
Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected) Karen McCullough MMI Associates (908) 534-6463 PDA Metro Chapter Day June 2, 2009 RISK is a four letter
More informationCGMP for 21 st Century : A Risk-based Approach (Quality by Design)
CGMP for 21 st Century : A Risk-based Approach (Quality by Design) Chung Keel Lee, Ph.D. Special Advisor to the Minister, MFDS Professor, EWU/SNU Advisor, WHO Chair, ISPE Korea 4Ms Four Basic Elements
More informationQuality Risk Management (QRM), according
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2011, Vol. 31 No. 4 www.ispe.org Copyright ISPE 2011 This article presents how the quality and utility of Quality Risk
More informationUpdate to the Manufacturing Principles for Medicinal Products
Update to the Manufacturing Principles for Medicinal Products Michel Lok, Head of Office Robyn Oatey, GMP Auditor, Medicines Office of Manufacturing Quality Therapeutic Goods Administration Introduction
More informationEFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT
EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago
More informationDealing with chance Four strategies. Simple, direct Absolutes. Persuasion Top management support. Training. Corruption Alienation. 3 lines of defense
Hazard avoidance overview Concepts of Hazard Avoidance Dealing with chance Four strategies Enforcement Psychological Engineering Analytical ١ ٢ Enforcement approach Simple, direct Absolutes Judgment Corruption
More informationClinically Relevant Dissolution Specifications: FDA Perspective and Initiatives
Clinically Relevant Dissolution Specifications: FDA Perspective and Initiatives 2015 GPhA CMC Workshop June 10, 2015 Paul Seo, Ph.D. Division Director (Acting) OPQ/ONDP/Division of Biopharmaceutics 1 Outline
More information2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11.
LITERATURE REVIEW: Risk management is well known and practiced in many industries and several industry task forces have developed guidance documents that facilitate risk management. Risk management for
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationList of Tables. Part I Guidelines for Hazard Evaluation Procedures
List of Tables Part I Guidelines for Hazard Evaluation Procedures 1.1 Popular Synonyms for Hazard Evaluation 12 1.2 CCPS Elements of Process Safety Management 13 1.3 Elements of Process Accidents 18 1.4
More informationTech-Clarity Insight: Quality Risk Management in Life Sciences. Preventing Failures, Protecting Patient Health
Tech-Clarity Insight: Quality Risk Management in Life Sciences Preventing Failures, Protecting Patient Health Tech-Clarity, Inc. 2010 Table of Contents Table of Contents... 2 Executive Overview... 3 Mitigating
More informationApproaches to Risk-Based Quality Management Quality by Design/Quality Systems
Your Partner in Quality Management Approaches to Risk-Based Quality Management Quality by Design/Quality Systems F-Crin Workshop on Risk Management in Clinical Trials Peter Schiemann, PhD Clinical Quality
More informationMatching Flows: The Development of Continuous Manufacturing of Biotech Products
Matching Flows: The Development of Continuous Manufacturing of Biotech Products Jeffrey C. Baker, Ph.D. Deputy Director, Office of Biotechnology Products, CDER By telecon to ECI s Integrated Continuous
More informationLearning Objectives. System-Based Thinking as Related to Systems-Based Inspections and Audits
SYSTEMS-BASED THINKING, RISK MANAGEMENT, AND CORPORATE CULTURE: Perspectives on 21 st Century Compliance Dennis J. Runser, Ph.D., RAC TMI Regulatory Compliance Consulting Learning Objectives 1) System-Based
More informationPractical Strategies for Improving Quality Risk Management activities in GMP environments
Practical Strategies for Improving Quality Risk Management activities in GMP environments Kevin O Donnell, Ph.D. Market Compliance Manager & Senior GMP Inspector, Irish Medicines Board, Ireland CMC Strategy
More informationPharmaceutical Quality-by-Design (QbD): Basic Principles
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Sharmada S. Sinai Kakodkar et al. Pharmaceutical Quality-by-Design (QbD): Basic Principles Keywords: Quality-by-design,
More informationResearch and Reviews: Journal of Pharmacy and Pharmaceutical Sciences
Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences Pharmaceutical Quality by Design: A New Approach in Product Development. Ashwini Gawade 1 *, Satyam Chemate 1, and Ashwin Kuchekar
More informationThe Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA
The Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA K. Witzmann, MD Inhalation and Drug-Device Combination Products Team Office of Research and Standards, Office
More informationDefine Risk and Risk levels-implementing ICH Q9 QUALITY RISK MANAGEMENT
I Define Risk and Risk levels-implementing ICH Q9 QUALITY RISK MANAGEMENT What is risk and what are the different Risk: types of risk we face The combination of the probability of occurrence of harm and
More informationRisk Management ICH Q9 - FMEA - Applied to Validation
Risk Management ICH Q9 - FMEA - Applied to Validation PBE, Pharma Bio Expert Inc PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Health Canada & expert, Training Company Agreement CPMT #0059104
More informationEnabling Improvement through the Product Lifecycle: Change Management within a PQS
Enabling Improvement through the Product Lifecycle: Change Management within a PQS Denise DiGiulio, Senior Advisor OPQ Office of Process and Facilities PDA Chapter Meeting Melbourne, Australia April 3,
More informationState of Office of Pharmaceutical Quality (OPQ) Address
State of Office of Pharmaceutical Quality (OPQ) Address Giuseppe Randazzo, M.S. Director, Office of Program and Regulatory Operations Office of Pharmaceutical Quality Center for Drug Evaluation and Research,
More informationRAM & LCC for railways Industry: What s really necessary to high performance achievement?
RAM & LCC for railways Industry: What s really necessary to high performance achievement? Despite the very well organized and clear information in standard EN 50126, additional RAMS methods must be implemented,
More informationAsset Management and Dependability Supporting the Business. James (Jim) Kennedy CPEng, CFAM, CAMA
Asset Management and Dependability Supporting the Business James (Jim) Kennedy CPEng, CFAM, CAMA Coverage Text The burning platform for change in Dependability standards Technical Committee TC 56 13 Countries
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationIS DIGITALIZATION JUST A BUZZ WORD FOR PROCESS SAFETY MANAGEMENT? Pascal Le Gal, PhD IIRSM Meeting, Abu Dhabi, April 4 th 2018
IS DIGITALIZATION JUST A BUZZ WORD FOR PROCESS SAFETY MANAGEMENT? Pascal Le Gal, PhD IIRSM Meeting, Abu Dhabi, April 4 th 2018 Currently Sales Director at Insight Numerics (UAE). Speciliazing in fire and
More informationOffice of Pharmaceutical Quality Progress Update
Office of Pharmaceutical Quality Progress Update Michael Kopcha, Ph.D., R.Ph. Director Office of Pharmaceutical Quality CDER/FDA 2017 3 rd PQRI/FDA Conference on Advancing Product Quality March 22-24,
More informationQuality Related to Tracked Safety Issues (TSI) An Ophthalmic Case Study
Quality Related to Tracked Safety Issues (TSI) An Ophthalmic Case Study Avin Lalmansingh, Ph.D. CDER/OPQ/OLDP/ Division of Post marketing Activities II 2017 AAM CMC Workshop May 24 th, 2017 DISCLAIMER
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationWARNING LETTER NO NOL-07
601GSS1~1. DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration New Orleans Dis trict 404 BNA Driv e Building 200 - Suite 500 Nashville, TN 3721 7 Telephone : (615) 366-7801 FAX : (615)
More informationProcess Validation And Risk Assessment Study of Loratadine Tablet
Vol: 3 Issue: 1 Process Validation And Risk Assessment Study of Loratadine Tablet *1 2 2 2 Vala Khushbu, Patel Chaitali, Rathava Rakesh, Rathod Dhara 1 Department of Pharmaceutical Chemistry, Parul Institute
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationBest Practices In Pharmaceutical Formulation Development
1 Best Practices In Pharmaceutical Formulation Development 18-05-2018 2 Who are we? Your partner in achieving excellence Sidvim provides experience based, specialized consultancy services across all functional
More informationChallenges in Getting Global Approvals for Post-approval Changes
Slide no 1 Supply Flexibility Program, ROFE 2009 Challenges in Getting Global Approvals for Post-approval Changes FDA/PQRI Conference on Evolving Product Quality September 17, 2014 Andrew Chang, Ph.D.
More informationEffective application of Risk Management techniques to Drug Safety: a pragmatic approach
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following
More informationRisk Assessment Techniques
This article was downloaded by: [Stephen N. Luko] On: 27 May 2014, At: 08:21 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer
More informationParadigm Change in Manufacturing Operations
Technical Report No. 54-4 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 3: Case Studies in the Manufacturing of Biotechnological Bulk Drug
More informationGeneric drugs and their role in bringing next generation products: An FDA perspective
Generic drugs and their role in bringing next generation products: An FDA perspective Markham C. Luke, MD, PhD Director, Division of Therapeutic Performance (DTP) Office of Generic Drugs, FDA, HHS February
More informationinventivhealthclinical.com The Goal: Reducing Uncertainty A Word on RBM
Seeing Around Corners: Risk Assessment Is the Foundation of Risk-Based Monitoring By: Jeff Fetterman, President ParagonRX, an inventiv Health Company, Michael Macri, Director, Strategic Services, inventiv
More informationA review on quality by design
Review Article DOI: 10.18231/2394-2797.2018.0001 Sachin L. Darkunde M-Pharm, Department of Quality Assuranc, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, Maharashtra,
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationDeveloping New Bioequivalence Approaches for Complex Products
Developing New Bioequivalence Approaches for Complex Products Robert Lionberger, Ph.D. Acting Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research,
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. Combination Product Updates, Initiatives, and Case Studies. Steven B. Hertz, P.E.
Combination Product Updates, Initiatives, and Case Studies Steven B. Hertz, P.E. Consumer Safety Officer, FDA/CDER/OPQ Agenda 1: CP Overview 2: CDER Updates : CP Application Info : Case Studies 5: Summary
More informationQuality Risk Management
Implementation of ICH Q8, Q9, Q10 Quality Risk Management International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More information